Clinical activity of FOLFIRI plus cetuximab in elderly patients ( pts) according to extended gene mutation status by next generation sequencing (NGS) in the CAPRI- GOIM trial
E. Martinelli, C. Cardone, T. Troiani, N. Normanno, et al.
Conclusions: Tolerability of cetuximab plus FOLFIRI was acceptable in elderly pts. Similar ORR and PFS were observed according to age groups. No major differences in adverse events were reported among the defined subgroups.
Comment Erika Martinelli, Medical Oncology, AOU Seconda Università degli Studi di Napoli (AOU-SUN):